Corrigendum to "Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-α agonist WY14643" [Free Radic. Biol. Med. 41: 579-589; 2006] (DOI:10.1016/j.freeradbiomed.2006.04.030);Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-α agonist WY14643

Free Radical Biology and Medicine

Volumn 41, Issue 4, 2006, Pages 579-589

  Collino, Massimo ^a   Aragno, Manuela ^a   Mastrocola, Raffaella ^a   Benetti, Elisa ^a   Gallicchio, Margherita ^a   Dianzani, Chiara ^a   Danni, Oliviero ^a   Thiemermann, Christoph ^b   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Free radicals; Hippocampus; Inflammation; Ischemia reperfusion; Oxidative stress; PPAR

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; CYCLOOXYGENASE 2; GLUTATHIONE; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPID PEROXIDASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; PROTEIN S100B; REACTIVE OXYGEN METABOLITE;

ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; HIPPOCAMPUS; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; STROKE;

EID: 33746051675     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.09.013     Document Type: Erratum

References (60)

1. del Zoppo G.J. Stroke and neurovascular protection. N. Engl. J. Med. 354 (2006) 553-555
2. Schaller B. Prospects for the future: the role of free radicals in the treatment of stroke. Free Radic. Biol. Med. 38 (2005) 411-425
3. Nita D.A., Nita V., Spulber S., Moldovan M., Popa D.P., Zagrean A.M., and Zagrean L. Oxidative damage following cerebral ischemia depends on reperfusion-A biochemical study in rat. J. Cell. Mol. Med. 5 (2001) 163-170
4. Traystman R.J., Kirsch J.R., and Koehler R.C. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J. Appl. Physiol. 71 (1991) 1185-1195
5. Ryter S.W., and Choi A.M. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. Antioxid. Redox Signalling 7 (2005) 80-91
6. Crack P.J., and Taylor J.M. Reactive oxygen species and the modulation of stroke. Free Radic. Biol. Med. 38 (2005) 1433-1444
7. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Alvarez D., Al-Dalain S., Martinez G., Leon O.S., and Springer J.E. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. 86 (2003) 545-555
8. Lerouet D., Beray-Berthat V., Palmier B., Plotkine M., and Margaill I. Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats. Brain Res. 958 (2002) 166-175
9. Frijns C.J., and Kappelle L.J. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 33 (2002) 2115-2122
10. Foerch C., Singer O.C., Neumann-Haefelin T., du Mesnil de Rochemont R., Steinmetz H., and Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch. Neurol. 62 (2005) 1130-1134
11. Marenholz I., Heizmann C.W., and Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 322 (2004) 1111-1122
12. Shirasaki Y., Edo N., and Sato T. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res. 1021 (2004) 159-166
13. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10 (1999) 245-257
14. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
15. Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71 (2003) 315-325
16. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275 (2000) 36703-36707
17. Pahan K., Jana M., Liu X., Taylor B.S., Wood C., and Fischer S.M. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J. Biol. Chem. 277 (2002) 45984-45991
18. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
19. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P.K., and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 16 (2002) 1027-1040
20. Toyama T., Nakamura H., Harano Y., Yamauchi N., Morita A., Kirishima T., Minami M., Itoh Y., and Okanoue T. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem. Biophys. Res. Commun. 324 (2004) 697-704
21. Chen J., and Simon R. Ischemic tolerance in the brain. Neurology 48 (1997) 306-311
22. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., and Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352 (2003) 203-206
23. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., and Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23 (2003) 6264-6271
24. Sharma B.K., and Kumar K. Role of proinflammatory cytokines in cerebral ischemia: a review. Metab. Brain Dis. 13 (1998) 1-8
25. Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131-145
26. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80
27. Meldrum D.R., Shenkar R., Sheridan B.C., Cain B.S., Abraham E., and Harken A.H. Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. J. Mol. Cell. Cardiol. 29 (1997) 2849-2854
28. Ravindranath V. Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. Methods Enzymol. 233 (1994) 610-619
29. Owens C.W., and Belcher R.V. A colorimetric micro-method for the determination of glutathione. Biochem. J. 94 (1965) 705-711
30. Esterbauer H., Koller E., Slee R.G., and Koster J.F. Possible involvement of the lipid-peroxidation product 4-hydroxynonenal in the formation of fluorescent chromolipids. Biochem. J. 239 (1986) 405-409
31. Millar C.G., and Thiemermann C. Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. Br. J. Pharmacol. 121 (1997) 1824-1830
32. Buyukuysal R.L. Protein S100B release from rat brain slices during and after ischemia: comparison with lactate dehydrogenase leakage. Neurochem. Int. 47 (2005) 580-588
33. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
34. Eklof B., and Siesjo B.K. The effect of bilateral carotid artery ligation upon the blood flow and the energy state of the rat brain. Acta Physiol. Scand. 86 (1972) 155-165
35. Vanella A., Sorrenti V., Gambera G., Castorina C., Di Giacomo C., Campisi A., Salva M., and Perez-Polo J.R. Lipid peroxidation in rat cerebral cortex during post-ischemic reperfusion: effect of exogenous antioxidants and Ca(++)-antagonist drugs. Ital. J. Biochem. 39 (1990) 196A-198A
36. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273 (1998) 32833-32841
37. Tsuchihashi S., Fondevila C., and Kupiec-Weglinski J.W. Heme oxygenase system in ischemia and reperfusion injury. Ann. Transplant. 9 (2004) 84-87
38. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., and Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987) 1043-1046
39. Otterbein L.E., Soares M.P., Yamashita K., and Bach F.H. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24 (2003) 449-455
40. Cuzzocrea S., Di Paola R., Mazzon E., Genovese T., Muia C., and Caputi A.P. WY14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22 (2004) 340-346
41. Okaya T., and Lentsch A.B. Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G606-G612
42. Sivarajah A., Chatterjee P.K., Hattori Y., Brown P.A., Stewart K.N., Todorovic Z., Mota-Filipe H., and Thiemermann C. Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med. Sci. Monit. 8 (2002) BR532-BR539
43. Bulhak A.A., Sjoquist P.O., Xu C.B., Edvinsson L., and Pernow J. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res. Cardiol. 101 (2006) 1-9
44. Yue T.L., Bao W., Jucker B.M., Gu J.L., Romanic A.M., Brown P.J., Cui J., Thudium D.T., Boyce R., Burns-Kurtis C.L., Mirabile R.C., Aravindhan K., and Ohlstein E.H. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108 (2003) 2393-2399
45. Despres J.P., Lemieux I., Pascot A., Almeras N., Dumont M., Nadeau A., Bergeron J., and Prud'homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 702-703
46. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., and Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36 (1998) 345-349
47. Combs C.K., Bates P., Karlo J.C., and Landreth G.E. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39 (2001) 449-457
48. Pang L., Nie M., Corbett L., and Knox A.J. Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J. Immunol. 170 (2003) 1043-1051
49. Meade E.A., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem. 274 (1999) 8328-8334
50. Mollace V., Muscoli C., Masini E., Cuzzocrea S., and Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev. 57 (2005) 217-252
51. Janabi N. Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14) (12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J. Immunol. 168 (2002) 4747-4755
52. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
53. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res. Cardiol. 97 (2002) 276-285
54. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., Legos J.J., Erhardt J.A., Ohlstein E.H., Hunter A.J., Harrison D.C., Philpott K., Smith B.R., Adams J.L., and Parsons A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 21 (2001) 129-145
55. Ozawa H., Shioda S., Dohi K., Matsumoto H., Mizushima H., Zhou C.J., Funahashi H., Nakai Y., Nakajo S., and Matsumoto K. Delayed neuronal cell death in the rat hippocampus is mediated by the mitogen-activated protein kinase signal transduction pathway. Neurosci. Lett. 262 (1999) 57-60
56. Shen W.H., Zhang C.Y., and Zhang G.Y. Antioxidants attenuate reperfusion injury after global brain ischemia through inhibiting nuclear factor-kappa B activity in rats. Acta Pharmacol. Sin. 24 (2003) 1125-1130
57. Irukayama-Tomobe Y., Miyauchi T., Kasuya Y., Sakai S., Goto K., and Yamaguchi I. Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes. J. Cardiovasc. Pharmacol. 44 (2004) S358-S361
58. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14 (1996) 649-683
59. Carter A.B., Knudtson K.L., Monick M.M., and Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression: the role of TATA-binding protein (TBP). J. Biol. Chem. 274 (1999) 30858-30863
60. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., and Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273 (1998) 3285-3290